Welcome to our dedicated page for Versigent PLC SEC filings (Ticker: VGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Versigent PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Versigent PLC's regulatory disclosures and financial reporting.
Vinci Sharon reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC Chief People Officer Vinci Sharon received a grant of 18,617 Ordinary Shares as compensation. The award was recorded at a price of $0.0000 per share, indicating it was not an open-market purchase. Following this grant, Sharon directly holds a total of 61,474 Ordinary Shares.
Versigent PLC chief legal officer and secretary Janis N. Acosta reported receiving two equity awards of the company’s Ordinary Shares. On April 22, 2026, she acquired 21,254 Ordinary Shares at $0.00 per share in a grant classified as a “grant, award, or other acquisition.” Following this grant, her reported direct holdings in that line were 39,871 shares.
On the same date, she received a second grant of 18,617 Ordinary Shares, also at $0.00 per share, with that line showing 18,617 shares held directly after the transaction. These transactions are compensation-related share awards rather than open‑market purchases or sales.
CELIAN JASON reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC Chief Accounting Officer Celian Jason received a stock grant of 6,982 Ordinary Shares on April 22, 2026. The award was recorded at a price of $0.0000 per share, indicating a compensation-related grant rather than an open-market purchase. Following this transaction, Jason directly holds 9,335 Ordinary Shares of Versigent PLC.
Versigent PLC reported that its Chief Financial Officer, Douglas R. Ostermann, received a grant of 43,438 Ordinary Shares as a stock award. The shares were acquired at a reported price of $0.00 per share, indicating a compensation-related grant rather than a market purchase.
Following this award, the CFO directly holds 169,542 Ordinary Shares. This filing reflects an equity-based compensation event and does not show any open-market buying or selling activity.
Liotine Joseph T. reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC disclosed that CEO and director Joseph T. Liotine received a grant of 111,698 Ordinary Shares on April 22, 2026. The award was recorded at a price of $0.00 per share, indicating it is a compensation-related equity grant rather than an open-market purchase. Following this grant, Liotine directly holds 230,153 Ordinary Shares.
Versigent PLC director Brad M. Cerepak received a grant of 5,168 Ordinary Shares as equity compensation. The shares were acquired on a non-cash basis at a reported price of $0.0000 per share. Following this award, he directly holds 5,168 Ordinary Shares, with no derivative positions reported.
Versigent PLC director Eric Kueppers received a grant of 5,168 Ordinary Shares. The shares were acquired on a non-market basis at a reported price of 0.0000 per share, indicating a compensation-related award rather than an open-market purchase. After this grant, his direct holdings total 5,168 Ordinary Shares.
Versigent PLC director Tamez Armando received a share grant reported on Form 4. He was awarded 5,168 Ordinary Shares on April 22, 2026 at a stated price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase.
After this award, his directly held ownership stands at 5,168 Ordinary Shares. The filing does not show any sales or derivative option exercises, only this single grant/award acquisition transaction.
Versigent PLC director Amy E. Alving received a share grant of 5,168 Ordinary Shares. The award was recorded at a price of $0.00 per share, indicating a compensation-related grant rather than a market purchase. Following this acquisition, she directly holds 5,168 Ordinary Shares.
MEISTER PAUL M reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC director Paul M. Meister received a stock award of 5,168 Ordinary Shares. The shares were granted at a reported price of $0.00 per share as a compensation-related award, not an open-market purchase or sale.
After this grant, he directly owns 11,561 Ordinary Shares. A footnote notes that his holdings include 6,393 Versigent Ordinary Shares previously received in a pro rata distribution from Aptiv PLC completed on April 1, 2026.